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SUMMARY
Objective: Pure primary ovarian choriocarcinomas are very rare, and the nongestational type is even more
uncommon. No definitive treatment protocol for this disease has been established due to its rarity. We report
the case of a 21-year-old female with a pure primary nongestational choriocarcinoma of the ovary and her
response to multidrug chemotherapy after surgery.
Case Report: The patient received seven courses of postoperative chemotherapy with etoposide, methotrexate,
actinomycin-D, cyclophosphamide and vincristine (EMA/CO) after suboptimal cytoreductive surgery. Serum
levels of the tumor marker `-human chorionic gonadotropin (`-HCG) dramatically decreased, and no evidence
of recurrence was detected. Unfortunately, the patient died of sepsis 7 months after diagnosis.
Conclusions: Pure primary nongestational choriocarcinoma is believed to have a poor prognosis. EMA/CO
proved to be useful in decreasing serum `-HCG levels in our patient, but more clinical experience is required
in the management of this aggressive malignancy. In addition, it is necessary to closely monitor the side effects
of the chemotherapy. [Taiwanese J Obstet Gynecol 2004;43(4):240–242]
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Introduction
Choriocarcinomas of the ovary are relatively uncommon
but aggressive germ-cell tumors. Most choriocarcinomas
are gestational in origin and arise primarily from the
uterus or Fallopian tubes, with those found in the ovary
mainly being metastases from these sites [1]. Thus,
nongestational choriocarcinoma of the ovary (NGCO)
is exceedingly rare. Pure NGCOs account for 0.6% or
less of all ovarian neoplasms [2]. The average age of
NGCO patients is usually less than 20 years, but a few
cases have occurred in patients more than 20 years old
[3]. Although an accurate diagnosis of nongestational
choriocarcinoma based on conventional histopatho-
logic investigations is virtually impossible if the patient
is of reproductive age, the diagnosis can be helped if
the NGCO occurs as a component of a mixed germ-cell
tumor or if it occurs in a virginal female [4]. Here, we
present a case of pure primary NGCO of International
Federation of Gynecology and Obstetrics (FIGO) stage
IIC. The patient received suboptimal cytoreductive sur-
gery and postoperative chemotherapy. Clinical charac-
teristics and outcomes of reported cases in the litera-
ture are briefly analyzed.
Case Report
A 21-year-old female presented with a 1-month history
of intermittent postprandial vomiting and weight loss.
She denied any sexual intercourse in the past. One
huge, irregular abdominal mass situated 2 cm below
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the umbilicus was noted. On examination, it was found
to be non-mobile. Sonographic evaluation showed a
huge hyperechoic mass with central hypoechogenicity
measuring about 12 = 10 = 10 cm, along with ascites in
the abdomen. The serum concentration of CA125 was
918.35 U/mL (normal, < 35 U/mL) and of ` -human cho-
rionic gonadotropin (`-HCG) was 1,787,052.3 mIU/mL
(normal, < 5 mIU/mL). Both carcinoembryonic anti-
gen and _-fetoprotein were within normal limits. Chest
roentgenography revealed mild left pleural effusion.
Cytology of the pleural effusion showed no malignant
cells. Computed tomography of the abdomen and pelvis
showed a left adnexal heterogeneous mass consistent
with ovarian cancer. Colonoscopy revealed intact muco-
sa in the entire colon.
After colon preparation, the patient underwent ex-
ploratory laparotomy under the impression of ovarian
cancer. During laparotomy, about 1 L of bloody ascites
was found. A fragile left ovarian tumor, measuring
about 15 = 15 = 10 cm, was found occupying the cul-de-
sac with invasion of the colon, rectum and posterior
uterine wall. The right Fallopian tube, omentum,
stomach and liver surface were grossly free of tumor
invasion. Suboptimal cytoreductive surgery including
left salpingo-oophorectomy and tumor excision was
performed due to severe pelvic adhesion and massive
bleeding during the dissection. The remaining main
tumor, more than 2 cm in size, was densely adherent to
the colon, rectum and posterior surface of the uterus.
Microscopically, sections of the left ovary revealed a
picture of choriocarcinoma. The tumor cells forming a
syncytial pattern were large, hyperchromatic and pleo-
morphic. Hemorrhage and necrosis were also seen. Cy-
tology of the ascites was positive for malignant cells.
The patient recovered smoothly after the operation.
Under the impression of a pure primary NGCO of
FIGO stage IIC, combination chemotherapy with EMA/
CO (300 mg/m2 methotrexate on day 1, 100 mg/m2
etoposide and 0.5 mg/m2 actinomycin-D on days 1–2,
and 600 mg/m2 cyclophosphamide and 1 mg/m2
vincristine on day 8) was scheduled. Response to che-
motherapy was reflected in the patient’s decreasing
serum levels of `-HCG (Figure). Seven courses of che-
motherapy were administered at irregular intervals
due to poor compliance by the patient. However, left
flank pain developed 1 week after the seventh course of
chemotherapy and ultrasound revealed left hydro-
nephrosis. Intravenous pyelography showed stenosis
over the lower portion of the left ureter. Subsequently,
a left double-J catheter was smoothly inserted by a urol-
ogist, and prophylactic antibiotics were prescribed
after the procedure. Unfortunately, 5 days later, high
fever and unconsciousness were noted. Empiric antibio-
tics were immediately prescribed for septic shock after
infectious workup. Despite the aggressive treatment,
she died the next day.
Figure. Decrease in ` -human chorionic gonadotropin (`-HCG) levels after cytoreductive surgery and combination chemotherapy
(C/T) with etoposide, methotrexate, actinomycin-D, cyclophosphamide and vincristine.
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Discussion
Pure primary choriocarcinomas of the ovary are usually
of gestational origin [5]. No distinctive ultrastructural
or immunohistochemical differences have been reported
between those of gestational and nongestational origin
[2]. However, ascertainment of the origin of the tumor
is important in selecting the most appropriate treatment
regimen and offering an accurate prognosis [6]. Con-
firmation of the gestational type relies on detectable
products of conception, while an NGCO is suggested
by a history of virginity or inability to conceive [7]. Diag-
nosis of an NGCO is also favored by the presence of a
choriocarcinoma admixed with other neoplastic germ-
cell elements. However, human leukocyte antigen typing
for paternal antigens and genetic analysis are by far the
most reliable tools in differentiating between gestational
and nongestational choriocarcinomas [1,4].
It is widely recognized that trophoblastic tumors
respond well to chemotherapy. Multiple-drug regimens
are proposed due to the possible occurrence of cross-
resistance due to sequential introduction of drugs.
EMA/CO to treat high-risk patients with gestational
trophoblastic diseases was initially introduced by
Bagshawe [8], and overall survival rates of more than
80% have been reported [9]. Two cases of advanced
pure primary NGCOs treated with adjuvant EMA/CO
chemotherapy have been reported [1,6]. They were
both Japanese women who presented with a painful
abdominal mass and multiple lung metastases. The di-
agnosis of pure NGCO was confirmed in both by DNA
polymorphism analysis. The EMA/CO regimen con-
sisted of 200 mg/m2 etoposide, 300 mg/m2 metho-
trexate, 1.0 mg actinomycin-D, 600 mg/m2 cyclophos-
phamide and 1.0 mg/m2 vincristine, but the interval
was not available. Serum levels of `-HCG were ele-
vated, given as 1,800 ng/mL in a 45-year-old woman
(normal, < 0.2 ng/mL) and 110,000 IU/L in a 19-year-
old virginal female (normal, < 5 IU/L). The first woman
died of respiratory failure due to disease progression
after four courses of chemotherapy following suboptimal
cytoreductive surgery; no decrease in the `-HCG level
was found. The second woman survived after multiple
courses of chemotherapy following cytoreductive sur-
gery, and the serum level of `-HCG returned to normal.
Our patient showed dramatically decreased serum
levels of `-HCG after surgery and chemotherapy but
still died of septic shock. Hematologic toxicity, the main
problem with this regimen, often requires dose reduc-
tions and treatment delays [10]. Successful treatment
usually hinges on shortened intervals of chemotherapy,
which overcome drug resistance. In addition, we need
to pay more attention to preventing all kinds of infectious
diseases during administration of the chemotherapy.
NGCO of the ovary is generally believed to have a
poor outcome [11], and several authors base the clini-
cal prognosis on surgical staging of the disease [4,12].
Long-term survival, unrelated to the size of the residual
tumors, can be achieved after combination chemothera-
py [3]. In spite of a clinical response to the chemotherapy
in our case, it is still important to pay special attention
to the hematologic toxicity of the EMA/CO regimen.
Although the addition of granulocyte colony-stimulating
factor to each cycle of this regimen may benefit patients
by achieving a proper dose intensity without adverse
effects [10], we need to emphasize the prevention of all
infections as much as is possible during the course of
chemotherapy. So far, the effectiveness of EMA/CO in
treating this aggressive carcinoma has not been well
documented, highlighting the need for greater clinical
experience in this area.
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